Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24003314 | 0.82 | TAAR1 (0.44) | CSNK2A1MAOBNOS3NOS1NOS2 | |
| SCHEMBL746669 | 0.79 | POLB (0.55) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL30670765 | 0.78 | CYP1A2 (0.56) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| SCHEMBL9809283 | 0.76 | MAOB (0.47) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL6574419 | 0.74 | MAOB (0.46) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| SCHEMBL22563306 | 0.74 | ST14 (0.45) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| SCHEMBL28475690 | 0.73 | KEAP1 (0.49) | ST14CSNK2A1MAOBKEAP1NFE2L2 | |
| SCHEMBL21501233 | 0.73 | MTNR1A (0.43) | MAOBPOLBSLC6A4 | |
| SCHEMBL22986087 | 0.73 | MTNR1A (0.43) | MAOBPOLBSLC6A4 | |
| SCHEMBL23674125 | 0.72 | MAOB (0.44) | ST14CSNK2A1MAOBKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | ST14 1435/4885CSNK2A1 3392/4885MAOB 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.